Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | AHR | P35869 | 3/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | GALK1 | P51570 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29891722 | 1.00 | DAO (0.62) | DAOCA12CA9BRD4BRPF1 | |
| SCHEMBL31426215 | 0.78 | DAO (0.65) | DAOCA12CA9BRD4BRPF1 | |
| SCHEMBL715895 | 0.78 | DAO (0.65) | DAOCA12CA9BRD4BRPF1 | |
| SCHEMBL11479451 | 0.78 | DAO (0.42) | DAOCA12CA9BRD4BRPF1 | |
| SCHEMBL31039545 | 0.77 | DAO (0.62) | DAOCA12CA9BRD4BRPF1 | |
| SCHEMBL30349848 | 0.77 | DAO (0.62) | DAOCA12CA9BRD4BRPF1 | |
| SCHEMBL8538250 | 0.77 | DAO (0.62) | DAOCA12CA9BRD4BRPF1 | |
| SCHEMBL10677691 | 0.77 | KDM4E (0.52) | DAOMCL1KMT2AAHRDDB1 | |
| SCHEMBL21955107 | 0.77 | DAO (0.62) | DAOCA12CA9BRD4BRPF1 | |
| SCHEMBL28165616 | 0.77 | DAO (0.62) | DAOCA12CA9BRD4BRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | claimed |
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-05-20 | — | — | US | claimed |
| WO-2018163217-A2 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-09-13 | — | — | WO | claimed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4541422-A2 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | Gilead Sciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250051320-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3873900-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GILEAD SCIENCES INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| EP-3873884-B1 | 3-(QUINOLIN-8-YL)-1,4-DIHYDROPYRIDO[3,4-D]PYRIMIDIN-2,4-DIONE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GILEAD SCIENCES INC (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20150218175-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| EP-2882724-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC | IRBM - Science Park S.p.A. (IT) | 2015-06-17 | — | — | EP | disclosed |
| US-9040712-B2 | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20140206661-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| WO-2014023754-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS THAT ARE AMELIORATED BY INHIBITION OF HDAC | IRBM - SCIENCE PARK S.P.A. (IT) | 2014-02-13 | — | — | WO | disclosed |
| US-20110160228-A1 | DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION | CENTRE NATIONAL DE LA RECHERCHE SCIENRIFIQUE (CNRS) | 2011-06-30 | — | — | US | disclosed |
| EP-2297075-A1 | DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION | Centre National de la Recherche Scientifique (C.N.R.S) (FR) | 2011-03-23 | — | — | EP | disclosed |
| EP-1273971-B1 | Process for photopolymerization by exposure of a photosensitive lithographic printing plate | FUJIFILM CORP (JP) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009147217-A1 | DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | DAO 220/4885CA12 1028/4885CA9 1908/4885 |
| US-20250051320-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DAO 3735/4885CA12 1764/4885CA9 3455/4885 |
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | CBR1, POR, CAT | DAO 292/4885CA12 733/4885CA9 998/4885 |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | DAO 529/4885CA12 961/4885CA9 2437/4885 |
| US-20210147364-A1 | A CATALYST BOUND ALPHA RADICAL AND SYNTHESIS OF OXO COMPOUNDS USING THE SAME | CBR1, POR, CAT | DAO 332/4885CA12 841/4885CA9 994/4885 |
| US-20150218175-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | SMN1; SMN2, SF3B5, SF3B1 | DAO 2429/4885CA12 4846/4885CA9 4383/4885 |
| US-20140206661-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | SMN1; SMN2, SF3B5, SF3B1 | DAO 2429/4885CA12 4846/4885CA9 4383/4885 |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | DAO 4307/4885CA12 3651/4885CA9 3398/4885 |
| US-20110160228-A1 | DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION | TUBB4A, TUBA4A, TUBGCP4 | DAO 1910/4885CA12 260/4885CA9 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.